| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| 50mg | |||
| 100mg | |||
| 250mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
L-368899 hydrochloride targets the oxytocin receptor (OXTR), a G protein-coupled receptor that mediates the effects of the neuropeptide oxytocin. Oxytocin plays a key role in uterine contraction during labor and in milk ejection during lactation. As a potent and selective antagonist with IC₅₀ values of 8.9 nM and 26 nM for rat and human uterine OTR, respectively, L-368899 HCl blocks the binding of oxytocin to its receptor. This prevents oxytocin-induced signaling and uterine contractions, making it useful as a tocolytic agent.
|
|---|---|
| ln Vitro |
The IC50 values of L-368,899 hydrochloride for rat and human uterine oxytocin receptors are 8.9 nM and 26 nM, respectively. It is a strong, orally accessible, non-peptide oxytocin receptor antagonist. In rat liver and kidney (IC50: 510 nM, 960 nM, 890 nM, and 2400 nM, respectively), L-368,899 exhibits minimal action on VP receptors [1].
In vitro, L-368899 hydrochloride is a potent antagonist of the oxytocin receptor. Its activity is demonstrated in radioligand binding assays using isolated human and rat uterus, with IC₅₀ values of 26 nM and 8.9 nM, respectively. These in vitro activities confirm its high affinity and selectivity for the oxytocin receptor. |
| ln Vivo |
In both rats and dogs, L-368,899 shows comparable pharmacokinetics. The t1/2 of L-368,899 in both species was two hours following a single intravenous administration. Furthermore, in rats or dogs, L-368,899 has a plasma clearance of 23 to 36 ml/min/kg. For dogs, the Vdss values of L-368,899 are 2.0 and 2.6 L/kg and 3.4 to 4.9 L/kg [2]. Oral access to L-368,899 is available. Oral bioavailability in rats at the 5 mg/kg dose was 14% in females and 18% in males. Moreover, oral bioavailability in male and female rats was 41% and 17%, respectively, at a dosage of 25 mg/kg [2].
In vivo, L-368899 hydrochloride is an orally bioavailable oxytocin receptor antagonist. It is used as a tocolytic agent for the prevention of preterm labor. It also prevents oxytocin-induced anti-anomalous pain and anti-nausea, and may be useful for the study of depression. Detailed in vivo efficacy data from specific animal models are not extensively reported in the available literature. |
| Enzyme Assay |
Non-cell-based receptor binding assays for L-368899 hydrochloride involve radioligand binding studies using membrane preparations from human and rat uterus. The receptor is incubated with a radiolabeled oxytocin ligand and varying concentrations of the compound. Its binding affinity (IC₅₀) is determined by measuring the displacement of the radiolabeled ligand, with values of 8.9 nM and 26 nM for rat and human uterine OTR, respectively.
|
| Cell Assay |
Cellular assays for L-368899 hydrochloride are performed using cells expressing the oxytocin receptor. Cells are treated with the compound at various concentrations, followed by stimulation with oxytocin. Downstream signaling, such as calcium mobilization, is measured. The compound's ability to inhibit oxytocin-stimulated signaling is quantified. IC₅₀ values for receptor antagonism are determined.
|
| Animal Protocol |
In vivo animal models for L-368899 hydrochloride include models of preterm labor, where the compound is administered orally to prevent uterine contractions. Models of pain and depression may also be used to study its effects. The compound is administered via appropriate routes, and efficacy is assessed by measuring uterine contractions, pain responses, or behavioral parameters.
|
| ADME/Pharmacokinetics |
L-368899 hydrochloride has a molecular weight of 591.23 g/mol and a molecular formula of C₂₆H₄₃ClN₄O₅S₂. Its CAS number is 160312-62-9. The compound is supplied as a solid with a purity of ≥99.97%. It is soluble in DMSO. Storage conditions: -20°C. The compound is an orally bioavailable oxytocin receptor antagonist. Detailed pharmacokinetic parameters such as half-life and bioavailability are not extensively reported.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for L-368899 hydrochloride are not extensively reported in the available literature. As a research compound, its safety profile would need to be established through standard preclinical toxicity assessments. The compound is intended for research use only and is not for human consumption. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
|
| Additional Infomation |
L-368899 hydrochloride is a potent, selective, orally bioavailable, non-peptide oxytocin receptor antagonist. It has IC₅₀ values of 8.9 nM and 26 nM for rat and human uterine oxytocin receptors, respectively. It is used as a tocolytic agent and may be useful for the study of depression. Its CAS number is 160312-62-9.
|
| Molecular Formula |
C26H43CLN4O5S2
|
|---|---|
| Molecular Weight |
591.226423501968
|
| Exact Mass |
590.236
|
| CAS # |
160312-62-9
|
| Related CAS # |
L-368,899;148927-60-0
|
| PubChem CID |
90488775
|
| Appearance |
Light yellow to yellow solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
38
|
| Complexity |
1040
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1=CC=CC=C1N2CCN(CC2)S(=O)(=O)CC34CCC(C3(C)C)C[C@@H]4NC(=O)[C@H](CCS(=O)(=O)C)N.Cl
|
| InChi Key |
GIUFQWFJHXXXEQ-PHSYAEQHSA-N
|
| InChi Code |
InChI=1S/C26H42N4O5S2.ClH/c1-19-7-5-6-8-22(19)29-12-14-30(15-13-29)37(34,35)18-26-11-9-20(25(26,2)3)17-23(26)28-24(31)21(27)10-16-36(4,32)33;/h5-8,20-21,23H,9-18,27H2,1-4H3,(H,28,31);1H/t20?,21-,23-,26?;/m0./s1
|
| Chemical Name |
(2S)-2-amino-N-[(2S)-7,7-dimethyl-1-[[4-(2-methylphenyl)piperazin-1-yl]sulfonylmethyl]-2-bicyclo[2.2.1]heptanyl]-4-methylsulfonylbutanamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~130 mg/mL (~219.88 mM)
H2O : ~50 mg/mL (~84.57 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.17 mg/mL (3.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.17 mg/mL (3.67 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.17 mg/mL (3.67 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6914 mL | 8.4569 mL | 16.9139 mL | |
| 5 mM | 0.3383 mL | 1.6914 mL | 3.3828 mL | |
| 10 mM | 0.1691 mL | 0.8457 mL | 1.6914 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA